Did someone forward this newsletter to you?
Sign up here to receive the Morning Rise for free.
Is the Psychedelics Industry Running Too Fast and Too Furious?
Psychedelics researchers keep coming up with news ways to help human health and wellness. And it’s not just mental health issues, such as PTSD and depression...
Mind Cure Continues Its Winding Down Process
After the market closed on Wednesday, Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) announced its financial results for the quarter ending November 30, 2022...
Psychedelic Enthusiasm Skips the Study of Side Effects
Most psychedelics clinical trials have some degree of failure in that there are people in the trial who simply can’t tolerate psychedelics as a therapeutic option—usually called adverse events...
Irwin Naturals Signs LOI to Acquire Braxia Scientific
Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) has entered into a nonbinding amended and restated letter of intent to purchase medical research company Braxia Scientific Corp...
In Other News
Satori Capital
Satori Capital, a multistrategy investment firm founded on the principles of conscious capitalism, announced the launch of a new business focused on transformational companies developing innovative solutions for mental health. Satori Neuro targets companies developing breakthrough treatments and disruptive business models to address the world’s most critical mental health challenges. Read more here.
People Science
People Science, a direct-to-consumer scientific research company providing a scaled research and development platform for alternative medicines, announced $5.3 million in a second seed round of funding led by Acre Venture Partners with participation from Bluestein Ventures, THIA Ventures, and FORM Life Ventures. This brings their total seed funding to $8.5 million. The company will use the new capital to support their expansion into nutrition and food as medicine alongside their existing research efforts on natural and synthetic psychedelics, the microbiome, cannabis and cannabinoid medicines and digital health interventions. Read more here.
Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN) received approval from an independent ethics committee in the Netherlands to initiate first-in-human dosing of its proprietary deuterated N,N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E Phase 1 trial. Read more here.
Feb. 2-4: Cannadelic Miami
March 10-12: SXSW Psychedelics Track, Austin, Texas
March 30-April 2: Convergence, Los Angeles
April 13: Benzinga Psychedelics Capital Conference, Miami Beach
Facebook Twitter Instagram YouTube RSS
Green Market Report © 2017 – 2023. All rights reserved.
Unsubscribe     Email Preference     Subscribe     Advertise
Back to Top